Dublin, Feb. 19, 2021 (GLOBE NEWSWIRE) -- The "US General Anesthesia Drugs Market by Route of Administration (Intravenous, Inhalational) and End-user (Hospitals, Ambulatory Surgery Centers) - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The US general anesthesia drugs market is projected to reach USD 2.4 billion by 2025 from USD 2 billion in 2020, at a CAGR of 3.4% during the forecast period.
The major factors driving the growth of this market are the rapid growth in geriatric population, rising prevalence of cancer and increasing number of emergency surgeries. However, issues related to the side effects of general anesthesia drugs in pregnant women and children are likely to restrain the market growth to a certain extent.
By route of administration, the intravenous drugs accounted for the largest share of the US general anesthesia drugs market
The intravenous drugs segment is expected to account for the largest market share in 2020. Factors such rapid onset of action, introduction of new anesthesia drugs with desired pharmacologic effects is expected to drive the market of intravenous anesthesia drugs. Moreover, intravenous anesthesia drugs are less expensive and do not require expensive machines for administration which contributes to the high market share of the segment.
Among intravenous anesthesia drugs, propofol accounted for the major share of the market in 2020. Smooth onset of action, high rate of total body clearance and less side effects are some of the factors contributing to high uptake of propofol as an anesthetic agent.
By End-user, Hospitals accounted for the largest share of the US general anesthesia drugs market
The hospitals segment accounted for the largest share of the US general anesthesia drugs market in 2019. The massive patient footfall in hospitals and the increasing number of surgeries performed in these facilities are the factors responsible for the largest share of the segment.
The report segments the US general anesthesia drugs market based on route of administration ((inhalational (sevoflurane, desflurane, isoflurane and nitrous oxide) and intravenous (propofol, benzodiazepines, ketamine, methohexital sodium and others)) and end-user (hospitals and ambulatory surgery centers). Company type (Tier 1, tier 2, Tier 3 providers of general anesthesia drugs). The report also provides a comprehensive review of market drivers, challenges, and opportunities in the US general anesthesia drugs market.
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 US General Anesthesia Drugs Market Overview
4.2 US General Anesthesia Drugs Market, by End-user, 2020 Vs. 2025
5 Market Overview
5.1 Market Analysis
5.2 Market Dynamics
126.96.36.199 Rapid Growth in the Geriatric Population
188.8.131.52 Rising Prevalence of Cancer
184.108.40.206 Rising Number of Emergency Surgeries
220.127.116.11 Risks Associated with General Anesthesia in Pediatric Patients and Pregnant Women
18.104.22.168 Patent Expiry of Lusedra
5.3 Market Size
5.3.1 Historical Market Trends, 2016-2019
5.3.2 Market Forecasts, 2020-2025
5.4 Impact of COVID-19 on the Growth of the US General Anesthesia Drugs Market
6 Distribution Structure
6.1 US Ketamine Market: Distribution Structure
6.1.1 US Ketamine Market, by Manufacturer
6.1.2 US Ketamine Market, by Distribution Channel
22.214.171.124 Group Purchasing Organizations
6.2 Key Legal Trends for Controlled Substances
6.2.1 Compliance Associated with the Manufacturing of Narcotics in the US
126.96.36.199 Labeling and Packaging
6.2.2 Compliance Associated with Vendors of Narcotics in the US
6.3 Product Category Enumeration
6.3.2 Other Brands
7 US General Anesthesia Drugs Market: Key Information
7.1 Import & Export Systems in the US
7.1.1 Import of Controlled Substances
188.8.131.52 Shipment of Controlled Substances
184.108.40.206 Registration of Applicants for the Import and Export of Controlled Substances
7.1.2 Export of Controlled Substances
220.127.116.11 Exceptions in Exportation for Special Scientific Purposes
18.104.22.168 Custom Tariffs for Imports
7.1.3 Transport of Controlled Substances
7.1.4 Customs Clearance
7.1.5 Non-Tariff Barriers
7.2 Top Related Exhibitions
7.3 Description of Potential Buyers
8 Product Analysis
8.1 Anesthesia Drugs Market Segmentation in the US
8.2 General Anesthesia
8.2.2 General Anesthesia Drugs Market Segmentation
8.3 Intravenous General Anesthetics
8.4 Inhalational General Anesthetics
8.4.1 Major Brands/Molecules
22.214.171.124 Methohexital Sodium
8.5 Competition in the US
8.5.1 Sales Price
8.5.2 Major Brands
8.6 Potential Buyers in the US
8.6.1 Potential Buyers, by State
9 US General Anesthesia Drugs Market, by End-user
126.96.36.199 Growing Patient Pool in Hospitals to Drive Market Growth
9.1.2 Ambulatory Surgery Centers
188.8.131.52 Increasing Number of ASCs in the Country to Boost the Market Growth
10 Competitive Landscape
10.2 Market Share Analysis (2019)
10.3 Key Market Developments
10.3.1 Product Launches
11 Company Evaluation Matrix and Company Profiles
11.2 Competitive Leadership Mapping: Major Market Players (2019)
11.2.2 Emerging Leaders
11.2.3 Pervasive Players
12 Company Profiles
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Fresenius SE & Co. KGaA
Heritage Pharmaceuticals Inc.
Hikma Pharmaceuticals plc
Merck & Co. Inc.
Piramal Enterprises Limited
For more information about this report visit https://www.researchandmarkets.com/r/1w87m7
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900